Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of vulvar disease characteristics and clobetasol feasibility in women with vulvar premalignant or malignant conditions versus healthy volunteers
2020-002201-25Phase 4Terminated
- Sponsor
- Centre for Human Drug Research
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of clobetasol in Kraurosis vulvae, vulvar intraepithelial neoplasia (VIN) and Vulval carcinoma (3 cohorts), sponsored by Centre for Human Drug Research. Primary endpoint: Comparable biomarker measurements over time and within each subgroup. Started Jul 2020; status: terminated.
02
Drugs
clobetasol
03
Conditions
Kraurosis vulvaevulvar intraepithelial neoplasia (VIN)Vulval carcinoma
Beyond the preview
Go deeper on 2020-002201-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002201-25.